Henry Schein, Inc. (NASDAQ:HSIC) Receives $77.10 Consensus Target Price from Analysts

Henry Schein, Inc. (NASDAQ:HSIC) has been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $77.10.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. UBS Group reduced their target price on shares of Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Robert W. Baird reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Baird R W raised shares of Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Finally, Barrington Research reduced their target price on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th.

Henry Schein Stock Down 1.2 %

Henry Schein stock opened at $69.00 on Wednesday. The firm has a market capitalization of $8.84 billion, a PE ratio of 23.31, a P/E/G ratio of 1.80 and a beta of 0.87. The company’s 50-day moving average is $67.81 and its 200-day moving average is $71.25. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.75 and a quick ratio of 1.02.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.01. The company had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.27 billion. Henry Schein had a net margin of 3.12% and a return on equity of 13.51%. Henry Schein’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.31 EPS. Sell-side analysts anticipate that Henry Schein will post 5.16 earnings per share for the current year.

Institutional Trading of Henry Schein

A number of institutional investors have recently bought and sold shares of HSIC. Swedbank AB bought a new stake in Henry Schein in the 1st quarter valued at about $215,998,000. Boston Partners raised its position in shares of Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after buying an additional 1,556,831 shares in the last quarter. Norges Bank acquired a new position in shares of Henry Schein in the 4th quarter valued at approximately $111,715,000. Nuance Investments LLC acquired a new position in shares of Henry Schein in the 4th quarter valued at approximately $103,446,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $46,683,000. Institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.